Aptevo Jumps 39% on Positive Data

Aptevo Therapeutics Inc. shares surged 29% on Friday after the company said a phase 2 trial showed “significant increase in median progression free survival” from approximately 10 to 16 months in patients receiving combination otlertuzumab/bendamustine therapy.

The results were recently published in the British Journal of Haematology (BJH). The trial studied the impact of a combination of otlertuzumab and bendamustine therapy on patients with chronic lymphocytic leukemia.

“These data, coupled with additional results from ongoing studies of otlertuzumab used in combination with current CLL therapies should help position otlertuzumab for a potential partnership to advance into phase 3 clinical development,” CEO Marvin White said.

Leave a Comment